title: [Is hepatitis B antigenemia a risk in adjuvant cytostatic treatment of breast cancer?].
abstract: One-hundred and fifteen consecutive patients with breast cancer were examined for hepatitis B. All the patients received adjuvant chemotherapy. The median age was 46 years (range 26-54 years). None of the patients were found to be HBsAg-positive. The prevalence of HbsAg was within the limits of 0-0.026 (95% confidence interval). Vaccination of patients receiving chemotherapy is not indicated. Furthermore, regular HBsAg screening among patients under 55 years cannot be recommended.
authors.forename: D
authors.initials: D
authors.lastname: Rasmussen
authors.forename: P L
authors.initials: PL
authors.lastname: Frederiksen
authors.forename: P M
authors.initials: PM
authors.lastname: Larsen
authors.forename: P
authors.initials: P
authors.lastname: Schlichting
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000276:immunology*; D005260:Female; D006511:Hepatitis B Antigens / Q000032:analysis*; D006801:Humans; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents; D006511:Hepatitis B Antigens
vernacular_title: Er hepatitis B antigenaemi en risiko ved adjuverende cytostatisk behandling for cancer mammae?